LivaNova (LIVN) Liabilities and Shareholders Equity (2015 - 2026)
LivaNova (LIVN) posted Liabilities and Shareholders Equity of $2.5 billion for Q1 2026, down 3.44% sequentially from $2.6 billion in Q4 2025, and down 1.66% YoY from $2.6 billion in Q1 2025.
LivaNova (LIVN) Liabilities and Shareholders Equity (2015 - 2026) Analysis & Trends
LivaNova has reported Liabilities and Shareholders Equity for 12 years, with the latest figure at $2.5 billion in Q1 2026.
- Quarterly Liabilities and Shareholders Equity fell 1.66% year-over-year to $2.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.2 billion (up 20.66% YoY) and the FY2025 annual result came in at $2.6 billion, up 3.98% from the prior year.
- Liabilities and Shareholders Equity eased to $2.5 billion in Q1 2026 per LIVN's latest filing, from $2.6 billion in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $2.6 billion in Q4 2025 and troughed at $855.1 million in Q2 2024.
- A 5-year average of $2.3 billion and a median of $2.4 billion in 2023 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity sank 63.48% in 2024, then jumped 193.15% in 2025.
- Over 5 years, Liabilities and Shareholders Equity stood at $2.3 billion in 2022, then increased by 5.87% to $2.4 billion in 2023, then gained by 3.16% to $2.5 billion in 2024, then increased by 3.98% to $2.6 billion in 2025, then retreated by 3.44% to $2.5 billion in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $2.5 billion, $2.6 billion, and $2.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.91 Bn | 193.31 Bn | 7.27 Bn | 109.22 Bn |
| 2 | Stryker | 127.59 Bn | 124.11 Bn | 4.50 Bn | 47.93 Bn |
| 3 | Medtronic | 118.77 Bn | 109.55 Bn | 6.41 Bn | 93.03 Bn |
| 4 | Boston Scientific | 73.24 Bn | 72.70 Bn | 3.85 Bn | 45.22 Bn |
| 5 | Edwards Lifesciences | 51.91 Bn | 47.66 Bn | 1.35 Bn | 13.87 Bn |
| 6 | Dexcom | 34.38 Bn | 32.44 Bn | 830.00 Mn | 6.46 Bn |
| 7 | GE HealthCare Technologies | 33.96 Bn | 31.85 Bn | 2.18 Bn | 37.25 Bn |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | 31.04 Bn |
| 9 | Steris | 23.08 Bn | 22.60 Bn | 684.20 Mn | 10.74 Bn |
| 10 | LivaNova | 4.29 Bn | 3.77 Bn | 273.67 Mn | 2.64 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.64 Bn |
| Mar 31, 2026 | 2.52 Bn |
| Dec 31, 2025 | 2.61 Bn |
| Sep 30, 2025 | 2.56 Bn |
| Jun 30, 2025 | 2.51 Bn |
| Mar 31, 2025 | 2.56 Bn |
| Dec 31, 2024 | 2.51 Bn |
| Sep 30, 2024 | 2.52 Bn |
| Jun 30, 2024 | 855.10 Mn |
| Mar 31, 2024 | 2.46 Bn |
| Dec 31, 2023 | 2.43 Bn |
| Sep 30, 2023 | 2.33 Bn |
| Jun 30, 2023 | 2.34 Bn |
| Mar 31, 2023 | 2.29 Bn |
| Dec 31, 2022 | 2.29 Bn |
| Sep 30, 2022 | 2.21 Bn |
| Jun 30, 2022 | 2.34 Bn |
| Mar 31, 2022 | 2.42 Bn |
| Dec 31, 2021 | 2.20 Bn |
| Sep 30, 2021 | 2.20 Bn |